Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012

Herbert Pang, Xiaofei Wang, Thomas E. Stinchcombe, Melisa L. Wong, Kit‐man Cheng, Apar Kishor Ganti, Daniel J. Sargent, Ying Zhang, Chen Hu, Sumithra J. Mandrekar, Mary W. Redman, Judith Manola, Richard L. Schilsky, Harvey Jay Cohen, Jeffrey D. Bradley, Alex A. Adjei, David R. Gandara, Suresh S. Ramalingam, Everett E. VokesJournal of Clinical Oncology 2016 · DOI

TL;DR

This study analyzed over two decades of lung cancer clinical trial enrollment data, revealing significant improvements in the representation of elderly patients with non-small-cell lung cancer (NSCLC) and women. However, disparities persist for elderly patients with small-cell lung cancer (SCLC) and racial/ethnic minorities, highlighting the need for targeted interventions to ensure trial results are generalizable to the broader lung cancer patient population.

What Problem Does This Paper Address?

Clinical trials are crucial for advancing cancer treatment, but their results are only truly valuable if they reflect the diversity of the patient population. Historically, certain groups, including the elderly, women, and racial/ethnic minorities, have been under-represented in these trials. This under-representation can lead to treatments that are less effective or have different side effect profiles in these populations, limiting the generalizability of research findings. This paper specifically addresses the long-term trends and persistent disparities in the enrollment of these demographic groups in National Cancer Institute (NCI)-sponsored lung cancer clinical trials from 1990 to 2012, comparing trial participants to the broader US lung cancer population.

Methods

The researchers employed a longitudinal, comparative analysis. They utilized data from two primary sources: NCI-cooperative group lung cancer trials and the Surveillance, Epidemiology, and End Results (SEER) registry. To quantify enrollment disparities, they calculated two metrics: the Enrollment Disparity Difference (EDD), which is the absolute difference in subgroup proportion between the trial population and the US population, and the Enrollment Disparity Ratio (EDR), which is the ratio of these proportions. They then analyzed trends over time using joinpoint regression to calculate the Annual Percentage Change (APC) for subgroup proportions in both datasets and to test for significant changes in these trends. This approach allowed them to assess not only the existence of disparities but also whether they were improving or worsening over the 22-year study period.

Datasets

  • National Cancer Institute (NCI) Cooperative Group Lung Cancer Trials: Data from 23,006 patients enrolled in 131 NCI-sponsored lung cancer treatment trials activated between 1990 and 2010, with accruals through December 2012.
  • Surveillance, Epidemiology, and End Results (SEER) Registry: Data from 578,476 patients diagnosed with lung cancer in the US during the period 1990 to 2012, used as a benchmark for the general US lung cancer population.

Key Insights and Ideas

  • The NIH Revitalization Act of 1993 had a tangible impact: The study suggests that the mandate to include women and minorities in NIH-funded research likely contributed to the observed improvements in the enrollment of women in lung cancer trials.
  • Not all elderly patients are the same: The improvement in elderly enrollment was specific to NSCLC. Elderly patients with SCLC showed no improvement, indicating that disease subtype is a critical factor in enrollment disparities.
  • Distant disease enrollment is catching up for women: The improved representation of women in trials was particularly driven by those with distant NSCLC, suggesting that newer therapies or trial designs might be more appealing or accessible to this group.
  • Racial/ethnic minorities remain a significant challenge: Despite overall improvements in some areas, the under-representation of Black, Asian/Pacific Islander, and Hispanic patients in lung cancer trials persisted throughout the study period.
  • The choice of metrics matters: Using both EDD and EDR provides a more nuanced understanding of disparities, capturing both absolute differences and relative over/under-representation.

Key Results

  • Elderly patients with NSCLC: Enrollment disparity improved significantly (test of parallelism, P = .020). By 2010-2012, the EDD was 0.22 and EDR was 1.65, indicating continued, though reduced, under-representation.
  • Elderly patients with SCLC: No improvement in enrollment disparity was observed (APC = 0.20, P = .714), despite an increase in the proportion of elderly SCLC patients in the US population. Disparity remained high in 2010-2012 (EDD = 0.35, EDR = 3.82).
  • Women with lung cancer: Overall enrollment disparity closed by 2010-2012 (EDD = 0.03, EDR = 1.07), showing significant improvement.
  • Racial/ethnic minorities: Enrollment disparities persisted for Black, Asian/Pacific Islander, and Hispanic patients without significant improvement over the study period.
  • Targeted Agents: In trials with targeted agents (2001-2012), elderly patient enrollment was similar to non-targeted trials, but women were more represented in erlotinib trials (55.6%) compared to non-erlotinib trials (43.4%).

Limitations and Future Work

The authors acknowledge several limitations:

  • Restriction to NCI-cooperative group trials: This excludes trials sponsored by industry, non-profit organizations, or other NCI-funded non-cooperative groups, potentially limiting the generalizability of findings to all lung cancer trials.
  • Small sample sizes for certain minority groups: This limited the power to detect enrollment disparities for groups like American Indians/Alaska Natives.
  • Reliance on SEER data: While widely used, SEER data represents a sample of all lung cancer cases.

Future work should focus on:

  • Understanding barriers: Deeper investigation into why disparities persist for elderly SCLC patients and racial/ethnic minorities is crucial. This includes exploring barriers to trial awareness, access, and participation.
  • Targeted interventions: Developing and implementing strategies to specifically address the under-representation of these groups, such as culturally competent patient navigation and community-based outreach.
  • Subgroup analysis: Continuing to examine enrollment trends in more refined subgroups (e.g., by specific cancer subtypes, genetic mutations, or extent of disease) to inform personalized medicine approaches and trial design.
  • Elderly-specific trials: Continuing to design and conduct trials tailored for older adults, potentially incorporating comprehensive geriatric assessments.

Summary updated

Abstract

Purpose Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this study was to characterize enrollment trends and disparities by age, sex, and race/ethnicity in lung cancer trials. Methods We analyzed data for 23,006 National Cancer Institute cooperative group lung cancer trial participants and 578,476 patients with lung cancer from the SEER registry from 1990 to 2012. The enrollment disparity difference (EDD) and enrollment disparity ratio (EDR) were calculated on the basis of the proportion of each subgroup in the trial population and the US lung cancer population. Annual percentage changes (APCs) in the subgroup proportions in each population were compared over time. Results Enrollment disparity for patients ≥ 70 years of age with non-small-cell lung cancer improved from 1990 to 2012 (test of parallelism, P = .020), with a remaining EDD of 0.22 (95% CI, 0.19 to 0.25) and EDR of 1.65 (95% CI, 1.51 to 1.82) in 2010 to 2012. No improvement was seen for elderly patients with small-cell lung cancer (SCLC), with an APC of 0.20 ( P = .714) among trial participants, despite a rising proportion of elderly patients with SCLC in the US population (APC, 0.32; P = .020). Enrollment disparity for women with lung cancer improved overall, with the gap closing by 2012 (EDD, 0.03 [95% CI, 0.00 to 0.06]; EDR, 1.07 [95% CI, 1.00 to 1.16]). Enrollment disparities persisted without significant improvement for elderly women, blacks, Asians/Pacific Islanders, and Hispanics. Conclusion Under-representation in lung cancer trials improved significantly from 1990 to 2012 for elderly patients with non-small-cell lung cancer and for women, but ongoing efforts to improve the enrollment of elderly patients with SCLC and minorities are needed. Our study highlights the importance of addressing enrollment disparities by demographic and disease subgroups to better target under-represented groups of patients with lung cancer.
BibTeX
@article{pang2016enrollment,
  author = {Herbert Pang and Xiaofei Wang and Thomas E. Stinchcombe and Melisa L. Wong and Kit‐man Cheng and Apar Kishor Ganti and Daniel J. Sargent and Ying Zhang and Chen Hu and Sumithra J. Mandrekar and Mary W. Redman and Judith Manola and Richard L. Schilsky and Harvey Jay Cohen and Jeffrey D. Bradley and Alex A. Adjei and David R. Gandara and Suresh S. Ramalingam and Everett E. Vokes},
  title = {{Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012}},
  journal = {Journal of Clinical Oncology},
  year = {2016},
  doi = {10.1200/jco.2016.67.7088},
}
Figure